News | March 25, 2022
CHMP recommends EU approval of Roche’s new combination treatment for large B-cell lymphoma
Recommendation is based on pivotal data from the phase III POLARIX study
Recommendation is based on pivotal data from the phase III POLARIX study
The approval is based on new data from cohorts D and K of the KEYNOTE-158 trial
OxemiaTM (Desidustat) is an oral tablet formulation that is the first-in-India alternative to injectable erythropoietin-stimulating agents (ESAs)
Vabysmo is the only injectable eye medicine approved simultaneously in the US for wet AMD and DME, with flexible dosing regimens based on patient need
The drug is aimed at treating Covid-19 patients with Acute Respiratory Distress Syndrome (ARDS)
Orencia is the first FDA-approved therapy to prevent acute graft versus host disease following hematopoietic stem cell transplant
While continuing to offer its current breadth of genomic services, Biogazelle will become CellCarta's Center of Excellence for the development of complex genomic biomarker assays
The NDA for Desidustat is based on positive data from the DREAM-ND and DREAM-D Phase 3 trials in patients with Chronic Kidney Disease (CKD) Not on Dialysis and Dialysis
It adds Rezurock (belumosudil) an FDA-approved, first-in-class treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD)
Zydus’ Sitagliptin base contains the active moiety Sitagliptin in a different form than used in the branded reference product, Januvia (Sitagliptin Phosphate)
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)